CL2017003503A1 - Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a). - Google Patents

Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).

Info

Publication number
CL2017003503A1
CL2017003503A1 CL2017003503A CL2017003503A CL2017003503A1 CL 2017003503 A1 CL2017003503 A1 CL 2017003503A1 CL 2017003503 A CL2017003503 A CL 2017003503A CL 2017003503 A CL2017003503 A CL 2017003503A CL 2017003503 A1 CL2017003503 A1 CL 2017003503A1
Authority
CL
Chile
Prior art keywords
mica
express
chain
treatment
variable domain
Prior art date
Application number
CL2017003503A
Other languages
English (en)
Inventor
Sampayo Maria Carmen Molina
Gutierrez Juan Carlos Aguillon
Ribeiro Carolina Hager
Olate Roberto Aquiles Zúñiga
Muñoz Norberto Andrés Collazo
Araya Lorenzo Eugenio Leiva
Gonzalez Matias Fernando Gutierrez
Lobos Jaime Camilo Teneb
Trujillo Alfonso Enrique Romero
Donoso Bastian Nicolas Jerez
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Priority to CL2017003503A priority Critical patent/CL2017003503A1/es
Publication of CL2017003503A1 publication Critical patent/CL2017003503A1/es
Priority to PCT/CL2018/050151 priority patent/WO2019126895A1/es
Priority to US16/959,096 priority patent/US11518811B2/en
Priority to EP18894287.4A priority patent/EP3744737A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La invención corresponde a un anticuerpo humano bivalente anti-MICA completamente humano, formado por dos cadenas pesadas con dominio variable y por dos cadenas ligeras con dominio variable, o formado por dos cadenas con cuatro dominios de inmunoglobulinas; dominio variable de la cadena pesada y liviana unidos por una cadena simple (scFv) y dominios CH2 y CH3 de inmunolobulina, el cual se une específicamente a la subunidad α1 de MICA. El anticuerpo monoclonal desarrollado es capaz de neutralizar a la proteína MICA en su estado soluble, como también opzonizar células tumorales que expresen este antígeno. Al inactivar el antígeno MICA por alguno de los dos mecanismos, revierte la inactivación de las células NK y activa las funciones efectoras de los anticuerpos e induce la citólisis celular a través de CD16 (ADCC), estimulando la inmunidad adaptativa. Así, el anticuerpo monoclonal de la invención posee una cadena pesada variable de SEQ ID NO: 1 y tienen una cadena ligera variable de SEQ ID NO: 2 y sus formas de realización tienen varias posibilidades o modalidades, entre ellas: ácidos nucleicos, vectores, células, composiciones farmacéuticas que los comprenden, kits, métodos y usos de los anticuerpos logrados, para ser utilizados en el tratamiento del cáncer gástrico u otro tipo de cáncer cuyas células tumorales expresan MICA en forma soluble o abundamentemente en su superficie. </p>
CL2017003503A 2017-12-29 2017-12-29 Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a). CL2017003503A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2017003503A CL2017003503A1 (es) 2017-12-29 2017-12-29 Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).
PCT/CL2018/050151 WO2019126895A1 (es) 2017-12-29 2018-12-27 Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés "mhc class i chain-related gene a).
US16/959,096 US11518811B2 (en) 2017-12-29 2018-12-27 Human antibody and fragments thereof for use in the treatment of gastric cancer (GC) and other types of tumours expressing the MICA protein (MHC class I chain-related protein A gene)
EP18894287.4A EP3744737A4 (en) 2017-12-29 2018-12-27 HUMAN ANTIBODIES AND FRAGMENTS THEREOF FOR USE IN TREATMENT OF STOMACH CANCER (GC) AND OTHER TYPES OF TUMORS EXPRESSING MICA PROTEIN (MHC CLASS I CHAIN-RELATED PROTEIN A-GEN)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017003503A CL2017003503A1 (es) 2017-12-29 2017-12-29 Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).

Publications (1)

Publication Number Publication Date
CL2017003503A1 true CL2017003503A1 (es) 2018-06-01

Family

ID=63046450

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003503A CL2017003503A1 (es) 2017-12-29 2017-12-29 Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).

Country Status (4)

Country Link
US (1) US11518811B2 (es)
EP (1) EP3744737A4 (es)
CL (1) CL2017003503A1 (es)
WO (1) WO2019126895A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179627A1 (en) 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
HRP20220531T1 (hr) 2014-12-05 2022-06-10 Xyphos Biosciences Inc. Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
CA3016765A1 (en) * 2016-03-15 2017-09-21 Innate Pharma Anti-mica antibodies

Also Published As

Publication number Publication date
EP3744737A1 (en) 2020-12-02
WO2019126895A1 (es) 2019-07-04
EP3744737A4 (en) 2021-09-01
US20210139593A1 (en) 2021-05-13
US11518811B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
PE20191648A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
CY1124944T1 (el) Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
UY37325A (es) Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
PE20180798A1 (es) Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
CL2023001076A1 (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
AR104047A1 (es) Anticuerpos anti-ceacam6 y sus usos
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
CL2020002036A1 (es) Terapia de combinación del cáncer que incluye proteínas de unión multiespecíficas que activan a las células asesinas naturales
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
AR080663A1 (es) Proteinas de union especificas y sus usos
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123